Skip to main content
Erschienen in: Pediatric Rheumatology 1/2015

Open Access 01.12.2015 | Poster presentation

Juvenile chronic non-bacterial osteomyelitis (CNO): Long term course of disease and response to treatment in a large institutional cohort

verfasst von: T Schwarz, S Petzke, H Morbach, C Hofmann, M Beer, P Raab, HJ Girschick

Erschienen in: Pediatric Rheumatology | Sonderheft 1/2015

download
DOWNLOAD
print
DRUCKEN
insite
SUCHEN

Introduction

Chronic non-bacterial osteomyelitis (CNO) is an inflammatory disorder of the skeletal system of unknown etiology. Long-term follow-up and response to treatment data have rarely been reported. The aim of the study was to characterize the clinical, radiological, histological and laboratory data at juvenile CNO onset, and to analyze the long term treatment response.

Methods

The course of disease of 93 juvenile patients (58% female) with non-bacterial inflammatory bone lesions was evaluated retrospectively. 1098 patient visits and 558 MRI findings were reviewed. Clinical, radiological, histological and laboratory data were assessed at disease onset and for a median time of disease of 46 months.

Results

The mean age at disease onset was 10.9 years, the mean time between the first symptoms and the diagnosis of CNO was 11 months. 84% of the patients had multifocal bone lesions. Biopsy was performed in 80 patients. Only when bone biopsy was taken within 12 months of symptom onset, cellular infiltrates could be observed. At later time points, fibrosis, hyperostosis and bone edema predominated. 25% of all patients developed peripheral arthritis, 8% inflammatory bowel disease. The initial treatment consisted of non-steroidal anti-inflammatory drugs (NSAIDs). 37% of the patients required second line therapy consisting of sulfasalazine and short term oral corticosteroids, 8% of the patients required bisphosphonates or TNF-blocking agents. Median time to first clinical remission was 6.0 months and 94% of patients achieved clinical remission within the period under review. Median time to first radiological remission, however, was 27.4 months and only 67% of all patients achieved complete radiological remission. Time to remission was independent of the CNO being unifocal or multifocal. In detail analysis of the treatment response revealed that initiation of sulfasalazine treatment in NSAID non-responders led to a significant and sustained decline of the clinical, as well as the radiological number of lesions.

Conclusion

The rapid clinical improvement in CNO, following initiation of therapy with NSAIDs, is not accompanied by a likewise decrease of the number of radiological lesions. Treatment with sulfasalazine is effective in childhood CNO.
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://​creativecommons.​org/​licenses/​by/​4.​0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. The Creative Commons Public Domain Dedication waiver (http://​creativecommons.​org/​publicdomain/​zero/​1.​0/​) applies to the data made available in this article, unless otherwise stated.
Metadaten
Titel
Juvenile chronic non-bacterial osteomyelitis (CNO): Long term course of disease and response to treatment in a large institutional cohort
verfasst von
T Schwarz
S Petzke
H Morbach
C Hofmann
M Beer
P Raab
HJ Girschick
Publikationsdatum
01.12.2015
Verlag
BioMed Central
Erschienen in
Pediatric Rheumatology / Ausgabe Sonderheft 1/2015
Elektronische ISSN: 1546-0096
DOI
https://doi.org/10.1186/1546-0096-13-S1-P178

Weitere Artikel der Sonderheft 1/2015

Pediatric Rheumatology 1/2015 Zur Ausgabe

ADHS-Medikation erhöht das kardiovaskuläre Risiko

16.05.2024 Herzinsuffizienz Nachrichten

Erwachsene, die Medikamente gegen das Aufmerksamkeitsdefizit-Hyperaktivitätssyndrom einnehmen, laufen offenbar erhöhte Gefahr, an Herzschwäche zu erkranken oder einen Schlaganfall zu erleiden. Es scheint eine Dosis-Wirkungs-Beziehung zu bestehen.

Erstmanifestation eines Diabetes-Typ-1 bei Kindern: Ein Notfall!

16.05.2024 DDG-Jahrestagung 2024 Kongressbericht

Manifestiert sich ein Typ-1-Diabetes bei Kindern, ist das ein Notfall – ebenso wie eine diabetische Ketoazidose. Die Grundsäulen der Therapie bestehen aus Rehydratation, Insulin und Kaliumgabe. Insulin ist das Medikament der Wahl zur Behandlung der Ketoazidose.

Frühe Hypertonie erhöht späteres kardiovaskuläres Risiko

Wie wichtig es ist, pädiatrische Patienten auf Bluthochdruck zu screenen, zeigt eine kanadische Studie: Hypertone Druckwerte in Kindheit und Jugend steigern das Risiko für spätere kardiovaskuläre Komplikationen.

Betalaktam-Allergie: praxisnahes Vorgehen beim Delabeling

16.05.2024 Pädiatrische Allergologie Nachrichten

Die große Mehrheit der vermeintlichen Penicillinallergien sind keine. Da das „Etikett“ Betalaktam-Allergie oft schon in der Kindheit erworben wird, kann ein frühzeitiges Delabeling lebenslange Vorteile bringen. Ein Team von Pädiaterinnen und Pädiatern aus Kanada stellt vor, wie sie dabei vorgehen.

Update Pädiatrie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.